Business Context and Reporting Period
Company: Amphastar Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 4, 2021
Event: Entry into a new senior secured credit facility and termination of prior material definitive agreements.
Key Financial Metrics and Debt Structure
This filing details a refinancing transaction rather than operational financial results. Key debt metrics include:
- Total New Facility: $140,000,000 senior secured credit facility.
- Structure:
- $70,000,000 five-year secured term loan.
- $70,000,000 five-year revolving line of credit.
- Interest Rates:
- LIBO Rate loans: Base rate plus 1.75% to 2.50% margin.
- Base Rate loans: Base rate plus 0.75% to 1.50% margin.
- Margins are based on the Consolidated Total Net Leverage Ratio.
- Unused Commitment Fee: 0.20% to 0.35% on undrawn revolving amounts.
- Sublimits: $15,000,000 each for Swing Line Loans and Letters of Credit.
- Collateral: Secured by substantially all company assets; subsidiaries required to guarantee obligations.
Material Changes Versus Prior Period
The Company executed a significant refinancing of its debt structure:
- Refinancing: Proceeds were used to repay and satisfy in full all amounts owing to former senior lenders Cathay Bank and East West Bank.
- Terminations: The Company terminated multiple security agreements and business loan agreements with Cathay Bank and East West Bank dating from 2010 to 2020.
- Exception: Certain mortgage debt owing to East West Bank remains outstanding as "Permitted Debt" under the new agreement.
- Costs: The Company incurred immaterial termination fees and other fees associated with the transition.
Guidance, Covenants, and Risks
Financial Covenants: The Credit Agreement requires the maintenance of specific ratios tested quarterly:
- Maximum Consolidated Total Net Leverage Ratio: 2.50 to 1.00.
- Minimum Consolidated Fixed Charge Coverage Ratio: 1.25 to 1.00.
Events of Default: Includes nonpayment, covenant breaches, cross-defaults, bankruptcy, insolvency, and change of control. Default may result in immediate acceleration of obligations.
Use of Proceeds: Refinancing existing debt, working capital needs, and general corporate purposes.
Outlook/Guidance: The filing does not provide operational guidance, revenue forecasts, or management commentary on future business performance.
Investor Verification Checklist
- Verify the exact amount of "Permitted Debt" (mortgage debt) remaining with East West Bank.
- Review the full Credit Agreement (to be filed as an exhibit to the Q3 2021 Form 10-Q) for detailed definitions of leverage ratios and covenants.
- Confirm the specific interest rate margin applicable based on the Company's current Consolidated Total Net Leverage Ratio.
- Assess the impact of the new debt service requirements on future cash flow compared to the terminated agreements.